eXoZymes, Inc. is a development-stage biotechnology company focused on enzyme technology for synthetic biology and biomanufacturing applications. The company develops enzyme modules and cell-free exozyme biosolutions designed to support manufacturing processes in biotechnology. The firm was incorporated in Nevada in 2014 and rebranded from Invizyne Technologies, Inc. to eXoZymes, Inc. in February 2025.
The company operates with a lean structure of 31 full-time employees and is headquartered in Monrovia, California. As a development-stage enterprise, eXoZymes is in the process of advancing its enzyme technology platform rather than generating substantial commercial revenue at this time. The company's operations remain concentrated in the United States, with its primary focus on research and development activities related to its enzyme module and biosolution offerings.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.89 | $-0.89 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001641172-25-001744 | SEC ↗ |